FOXO4-DRI
FOXO4-DRI takes a different approach to cellular aging than most compounds referenced on this site: rather than supporting cell function, it's designed to selectively eliminate senescent ("zombie") cells.
Not currently stocked by KYIN Peptides, but available to order — see availability below.
What Is FOXO4-DRI?
FOXO4-DRI is a D-retro-inverso peptide — a synthetic peptide built from mirror-image (D-) amino acids in reverse sequence, a design technique that confers resistance to normal enzymatic degradation. It's engineered to disrupt the FOXO4-p53 interaction that senescent cells depend on to evade apoptosis (programmed cell death), competitively blocking that interaction so p53 is freed to trigger cell death specifically in senescent cells while sparing healthy ones.
Research Focus: A Senolytic Approach
Where compounds like Epitalon and SS-31 are studied for supporting existing cell function — telomerase activity and mitochondrial membrane integrity, respectively — FOXO4-DRI represents a distinct research strategy known as senolytics: selectively clearing damaged, senescent cells that accumulate with age rather than supporting cells that remain functional. See our Longevity & Cellular Health research overview for how it fits alongside KYIN's stocked longevity-focused peptides.
Clinical & Preclinical Trial Data
All data is preclinical, from a single landmark study (Baar et al., Cell, 2017). Using naturally aged mice, a chemotherapy-induced senescence model, and a fast-aging XPF-ERCC1-deficient mouse strain, intraperitoneal FOXO4-DRI (5mg/kg, three times weekly) reduced senescence markers (p21, γ-H2AX), improved kidney function markers, restored fur density in areas of alopecia, improved exercise tolerance, and accelerated recovery from doxorubicin chemotherapy, relative to controls. No human clinical trial has been conducted for any indication.
Availability
FOXO4-DRI is not part of KYIN Peptides' standard catalogue, but it is available to order — contact us directly and we'll source it for you.
FOXO4-DRI questions
What is FOXO4-DRI?
FOXO4-DRI is a D-retro-inverso peptide engineered to disrupt the FOXO4-p53 interaction that senescent ("zombie") cells depend on to evade apoptosis, competitively blocking that interaction so p53 is freed to trigger cell death specifically in senescent cells.
Is FOXO4-DRI a senolytic?
Yes. Unlike compounds that support cell function, FOXO4-DRI is designed to selectively eliminate senescent cells, making it a senolytic — a class of compound that takes a fundamentally different approach to cellular aging research than support-focused compounds.
Has FOXO4-DRI been tested in humans?
No. All data is preclinical, from a single landmark 2017 study in mice. No human clinical trial has been conducted for any indication.
Does KYIN Peptides sell FOXO4-DRI?
Not as part of our standard catalogue, but yes — it's available to order. Contact us directly and we'll source it for you.
Interested in sourcing FOXO4-DRI?
Contact us and we'll help you source it, or browse our stocked longevity-focused peptides.